Literature DB >> 7564150

[After-care of children and young adults surviving cancer. Initial recommendations by the late sequelae study group].

J D Beck1, K Winkler, D Niethammer, M Brandis, H Hertzberg, K von der Hardt, J Greil, M A Uberall, R Rossi, A Lamprecht-Dinnesen.   

Abstract

An increasing number of children suffering from cancer has been treated successfully during the last 25 years using therapy protocols of the Gesellschaft für Pädiatrische Onkologie und Hämatologie. The patients had to undergo an interdisciplinary treatment modality and a mostly intensive chemotherapy. Late effects could result from this approach for the now 20,000 survivors in the Federal Republik of Germany. The executive committee of the GPOH founded a working group for the detection of late effects stretching over all therapy studies. The first report of this group describes a spectrum of relevant late effects and proposes investigations for their detection.

Entities:  

Mesh:

Year:  1995        PMID: 7564150     DOI: 10.1055/s-2008-1046537

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  2 in total

1.  Survivorship after childhood cancer: PanCare: a European Network to promote optimal long-term care.

Authors:  Lars Hjorth; Riccardo Haupt; Roderick Skinner; Desiree Grabow; Julianne Byrne; Sabine Karner; Gill Levitt; Gisela Michel; Helena van der Pal; Edit Bárdi; Jörn D Beck; Florent de Vathaire; Stefan Essig; Eva Frey; Stanislaw Garwicz; Mike Hawkins; Zsuzsanna Jakab; Momcilo Jankovic; Bernarda Kazanowska; Tomas Kepak; Leontien Kremer; Herwig Lackner; Elaine Sugden; Monica Terenziani; Lorna Zadravec Zaletel; Peter Kaatsch
Journal:  Eur J Cancer       Date:  2015-05-06       Impact factor: 9.162

2.  Study protocol of the German "Registry for the detection of late sequelae after radiotherapy in childhood and adolescence" (RiSK).

Authors:  Tobias Bolling; Andreas Schuck; Hildegard Pape; Christian Rube; Barbara Pollinger; Beate Timmermann; Rolf D Kortmann; Karin Dieckmann; Normann Willich
Journal:  Radiat Oncol       Date:  2008-04-21       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.